Roughly 48 to 50 million Americans aged 12 or older have a substance use disorder in any given year, based on national survey data from SAMHSA’s annual household survey. That figure includes both drug and alcohol use disorders. When you narrow it to drug use disorders alone, the number is still in the tens of millions, with opioids, stimulants, and cannabis accounting for the largest shares.
The Overall Numbers
SAMHSA’s National Survey on Drug Use and Health is the most comprehensive annual count of substance use disorders in the United States. In 2024, about 10.2 million people received substance use treatment in the past year, but that represented only about 1 in 5 of those classified as needing it. That math puts the total number of people needing treatment somewhere around 53 million.
These totals include alcohol use disorder, which is by far the most common form of addiction in the country. But drug-specific disorders, covering everything from opioids and methamphetamine to cocaine and prescription stimulants, affect millions on their own.
Opioids Remain the Deadliest Crisis
An estimated 2.5 million adults had opioid use disorder in 2021, a figure that includes both prescription painkillers and heroin. That number alone would be significant, but what makes the opioid crisis uniquely devastating is the death toll. In 2024, 79,384 Americans died from drug overdoses, and opioids (particularly synthetic ones like fentanyl) drive the majority of those deaths. That’s roughly 217 overdose deaths every day.
Treatment for opioid use disorder exists and works well, but access remains limited. Only about 1 in 5 adults with opioid use disorder received medications designed to treat it in 2021, according to the National Institute on Drug Abuse. The gap between how many people need help and how many actually get it is one of the defining features of the crisis.
Stimulant Use Disorders Are Growing
Stimulants are the second major category of drug addiction in the U.S., and the numbers are substantial. In 2023, about 4.3 million people aged 12 or older had a stimulant use disorder. That umbrella category breaks down into three overlapping groups:
- Methamphetamine: 1.8 million people (0.6% of the population 12 and older)
- Prescription stimulants: 1.7 million people (0.6%), which includes medications prescribed for ADHD and similar conditions
- Cocaine: 1.3 million people (0.4%)
Some individuals have disorders involving more than one stimulant, which is why the combined total of 4.3 million is lower than adding those three numbers together. Methamphetamine in particular has surged in recent years and is increasingly found mixed with fentanyl, which complicates both the addiction itself and the overdose risk.
How Addiction Is Defined and Measured
The clinical term used in these surveys is “substance use disorder,” which replaced older labels like “abuse” and “dependence.” It’s diagnosed on a spectrum of mild, moderate, or severe based on how many of 11 possible symptoms someone experiences. Two or three symptoms qualify as mild. Six or more is severe, which is closest to what most people mean when they say “addiction.”
The symptoms cover patterns most people would recognize: needing more of a substance to get the same effect, unsuccessful attempts to quit, spending large amounts of time obtaining or recovering from a substance, continuing to use despite relationship or health problems, and experiencing withdrawal when stopping. A person doesn’t need to hit rock bottom to meet the clinical threshold. Someone with a mild disorder might still hold a job and maintain relationships while struggling with cravings and failed attempts to cut back.
Who Is Most Affected
Addiction doesn’t affect every group equally. Among racial and ethnic groups, American Indian and Alaska Native people had the highest rate of substance use disorders in 2022, at 24%. Asian Americans had the lowest rate at 9%. For most other racial and ethnic groups, including White, Black, Hispanic, and multiracial populations, the rates did not differ significantly from one another, generally falling in the mid-teens percentage range.
Age plays a major role too. Young adults between 18 and 25 consistently show the highest rates of illicit drug use. Opioid misuse rates were higher among multiracial, Black, and Hispanic populations than among White or Asian populations in 2022. Meanwhile, White Americans had the highest rates of heavy alcohol use and underage drinking compared with other groups.
The Treatment Gap
Perhaps the most striking number in all of this data is the treatment gap. In 2024, only about 19.3% of people who needed substance use treatment actually received it. That means more than 4 out of 5 people with a substance use disorder went without any form of treatment in the past year.
The barriers are layered. Cost and lack of insurance keep many people out. So does stigma, which can prevent people from seeking help even when it’s available. Geographic access is another factor: rural areas often have few or no addiction treatment providers. For opioid use disorder specifically, effective medications exist but remain underused because not enough providers are trained or willing to prescribe them.
The Financial Toll
Treatment spending on substance use disorders reached $13.1 billion in 2021, with about $7.3 billion spent on drug use disorders and $5.8 billion on alcohol use disorders. That figure only captures direct treatment costs. The full economic burden, including lost productivity, criminal justice involvement, and healthcare for overdose-related emergencies, runs far higher. Spending on mental health and substance use disorder treatment has grown at an average annual rate about 1 percentage point faster than overall medical spending, reflecting the expanding scope of the crisis.
These numbers, as large as they are, still undercount the true impact. They don’t include nursing home costs related to substance use, nor do they capture the economic losses from the nearly 80,000 overdose deaths each year, each representing decades of lost earning potential and family disruption.